Dr. Joseph Ragaz

Medical Oncologist & Clinical Professor
Faculty of Medicine
School of Population & Public Health
The University of British Columbia, Vancouver, BC, Canada

Dr. Joseph Ragaz - Clinical, Academic and Research Activities

Dr. Ragaz is a Medical Oncologist, Breast Cancer Specialist and Clinical Professor at the Faculty of Medicine's School of Population and Public Health (SPPH), University of British Columbia, (UBC), Vancouver, B.C., Canada.


During his 1977-2003 tenure at the British Columbia Cancer Agency [BCCA], Vancouver, BC, Dr. Ragaz subspecialized in Breast Cancer, developing multiple provincial, national and international Clinical Research Initiatives, some of those helping with changes of National and International Breast Cancer practice guidelines.

From 2003 to 2008, Dr. Ragaz was the Director of the Oncology Program, McGill University Health Centre, McGill University, Montreal, Quebec, Canada, where he helped to expand and modernize the MUHC Oncology activities.

2009 2018 [present]: In 2009, Dr. Ragaz opened the Vancouver-based Oncology Counselling, Research and Prevention Clinic, dedicated to in-depth counselling of patients with established Cancer and for Breast Cancer Prevention. Problematic issues are frequently discussed with current local, national and international opinion leaders. In addition to the counseling activities, and if required, an informed second opinion is provided.


2009-2018: Dr. Ragaz is currently active at the School of Population and Public Health [SPPH], University of British Columbia, working with teams of local and international academic collaborators on a variety of Cancer Epidemiology and Outcome projects - see below.They include a number of Breast cancer Epidemiology and Outcome projects, most of them presented between 2007 - 2016 at the International Fora such as ASCO & SABCS [see below "Ongoing Clinical Projects"]. Most are now reaching presently maturity and completion.Dr. Ragaz has also led at the UBC School of Population and Public Health a Postgraduate SPPH 524 course [Introduction to Medicine - the Public Health Perspective], for the SPPH Masters and PhD students.

Since 1977, Dr. Ragaz has initiated or worked on a number of national and international breast cancer studies, paving the way to concepts eventually accepted by International community such as Neoadjuvantchemotherapy and Radiation for early breast cancer [1978 - 1989]; role of aromatase inhibitors replacing surgical adrenalectomy [1978 - 1983]; loco-regional radiotherapy increasing survival of breast cancer patients after mastectomy, treated with chemotherapy [1985 - 2005]; or role of tissue microarrays identifying new genetic markers [2000 - 2003].


2005-2017: Board Member, Director, Cancer Advocacy Coalition of Canada (http://www.canceradvocacy.ca). Dr. Ragaz has been an active champion of patient's rights to access the best cancer care, as seen from his many activities and publications with the Cancer Advocacy Coalition of Canada.

Ongoing Clinical Projects, 2016-2018

1. Ragaz J, Shakeraneh S, K Wilson, Frohlich J, Qian H, Wong H, Spinelli J : Emerging paradigms of Estrogen-based HRT: Review Analyses of Breast Cancer, Cardiac Events and all-cause Event & Mortality outcomes. A Critical Review with guideline implications. 2018, Manuscript in Preparation (MIP).

2. Ragaz J, A. Coldman, KS Wilson, J Fox, Shakeraneh S, H Wong, and JJ Spinelli : Long-term breast cancer outcomes in Canada with special analyses of cancer care access and mortality reduction. 2018, MIP.

3. Pathological basis of the DCIS: Impact of early diagnosis. Ju-Yoon Y, Ragaz J. 2018, MIP.

4. Ragaz J, H Wong, and H Qian : Comparative Analysis of Breast Cancer (BrCa) Mortality Reduction among Regions of Canada between 1950 - 2004: Impact of Systemic and Diagnostic Guidelines after 1977, with Model Definition of Number of Potentially Avoided Annual Deaths (N-PAAD). 2018, MIP.

5. Ragaz J, Zheng Y, Jian-Guo Chen, Pingping Bao, Shakeraneh S, Hu X, Fox J, Wong H, Qian H, Wilson K, Muraca G, Simpson S, Spinelli JJ, Coldman A : Breast Cancer Outcomes in Urban and Rural China: Adverse Effects of Western Lifestyle, versus Benefits of Western Interventions. A Comparative Analysis with Canada.. 2018, MIP.

6. Ragaz J, H Qian, S Shakeraneh, Fox J, Wilson K, Simpson J, Y Yoon, and H Wong : Population rates of In-Situ breast cancer [DCIS] are associated with breast cancer (BrCa) Incidence and Mortality rates. A case for screening mammography. 2018, MIP.

7. Ragaz J, A Coldman, J Fox, KS Wilson, S Shakeraneh, Y Zheng, JJ Spinelli, P Bao, H Wong, JS Simpson, X-C Hu, and JG Chen : Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention. 2018, MIP.

8. Ragaz J, K Wilson, H Wong, et al. : Molecular Classification with 21 Gene Assay (Oncotype DX) in 362,398 ER Positive Breast Cancer Patients: Definition of Chemoresistance with guidelines implications fro British Columbvia, Canada and USA. 2018, MIP.

9. Ragaz J, A Brodie, Simpson E, D Jelacic, Spinelli J, M Hayes : Cox-2 expression and impact of Cox-2 on survival according to Aromatase and ER status: implications to Breast Cancer therapy with Aromatase and Cox2 Inhibitors. 2018, MIP.